What changed for ADHD
A plain English summary of what recently moved in the public data Voxsanity tracks for ADHD. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 28 July 2026 and 29 July 2026.
- Trials on record 1,617 to 1,612 (-5)
Newly subsidised on the PBS
No medicines were newly subsidised on the PBS for ADHD in July 2026. Voxsanity tracks 5 PBS-subsidised medicines for this condition; none of them was listed for the first time this month.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
Trials tracked for ADHD that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT06301516 · results posted 17 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06301516) looked at a virtual reality (VR) programme called "Impact VR" and involved 220 people in total — 55 young people in the VR group, 55 caregivers in the VR group, 55 young people in a comparison (control) group, and 55 caregivers in a comparison group. All 220 participants completed the study. The trial was measuring three things: a set of personality traits sometimes called "callous-unemotional" traits (things like limited empathy or uncaring behaviour), behaviour problems as reported by caregivers, and the abilit...
-
NCT04723719 · results posted 13 February 2026
According to the results reported on ClinicalTrials.gov, this trial involved 92 children or young people with ADHD. Participants were split into two groups: 47 received a sleep training program called SIESTA on top of their usual ADHD treatment, while 45 continued with their usual ADHD treatment only. The trial was measuring sleep patterns — both through a wrist-worn movement tracker (called actigraphy) and through sleep diaries filled in by participants or their families — at the start of the study, after the program ended, and at a follow-up point. The reported data shows the following aver...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06454604 · results posted 2 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 60 people across three groups: a "VR Passthrough" group (22 started, 16 completed), a "Virtual Reality" group (18 started, 16 completed), and a "Virtual Reality + Feedback" group (20 started, 17 completed). The trial was measuring whether wearing a virtual reality headset while doing homework affected how focused, concentrated, motivated, and effortful participants were. Participants completed 12 sessions over three weeks — the first two sessions were done without a headset (used as a starting point, or "baseline"), a...
-
NCT05102344 · results posted 12 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05102344) involved 39 children in total — 19 who received standard psychosocial treatment (the usual care group) and 20 who took part in an Animal Assisted Intervention program. All 39 participants completed the study with no drop-outs reported. The trial measured three things across two time points (8 weeks and 16 weeks): ADHD symptom levels as rated by parents and teachers, children's own sense of how they felt about themselves across areas like schoolwork, friendships, and appearance, and parent-rated social behaviours...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04999982 · results posted 2 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04999982) involved 45 young children showing signs of ADHD, along with their parents or caregivers. Twenty-two families were placed in the intervention group (called PRE-CARE), and 23 were in a "care as usual" comparison group. Of those who started, 16 in the PRE-CARE group and 17 in the comparison group completed the study. The trial was measuring several things over time: children's ADHD-related behaviours (rated by parents on a 0–54 scale), the number of community support services families were enrolled in, children's b...
-
NCT03638466 · results posted 2 May 2025
According to the results reported on ClinicalTrials.gov, this was a small pilot trial (NCT03638466) that enrolled just 7 participants in total — 4 in the placebo group and 3 in the high-dose SPN-810 (36 mg) group. One person in the SPN-810 group did not complete the study. The trial was primarily measuring changes in brain activity using a type of brain scan called fMRI (which tracks blood flow as a marker of brain activity) while participants took part in a computer task designed to simulate aggressive and provocative situations. It also looked at a behavioural "aggression score" from that co...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05778526 · results posted 28 March 2025
According to the results reported on ClinicalTrials.gov, this trial involved 90 participants split evenly across three groups of 30: one group took part in social skills training using virtual reality (VR), one group received traditional face-to-face social skills training, and one group was placed on a waitlist (meaning they did not receive any active training during the study period). The trial was measuring things like how well participants attended their sessions, their social skills, their ability to manage behaviour and emotions, and their satisfaction with the training they received. Al...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05777785 · results posted 25 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05777785) enrolled 106 adults and followed them over approximately two months. There was only one group — everyone received the active treatment — so there was no comparison group. The trial was measuring ADHD-related symptoms and attention using several questionnaires and tests, including a self-report ADHD symptom scale (the ASRS), a clinician's overall impression of change (the CGI-I), a computer-based attention test (the CPT-3), and a questionnaire about everyday thinking and planning skills (the BRIEF-A). Six particip...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04987762 · results posted 22 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT04987762) enrolled 103 participants who were given a medication called Adhansia XR. The trial was set up to track adverse events — that is, any unwanted or unexpected health occurrences — that participants experienced while taking the medication, from the time they first agreed to take part until up to seven days after their last dose. The reported data shows three separate adverse event figures for the single group of 103 participants, though the data as submitted does not clearly label what each individual number refers...
-
NCT03730194 · results posted 4 April 2023
According to the results reported on ClinicalTrials.gov, this trial looked at two approaches to managing sleep in young people: taking melatonin (a supplement), and a behavioural strategy called a "Bedtime Bank" (a structured approach to managing bedtime). The trial used a two-stage design. In the first stage, 20 participants were assigned to melatonin only and 20 to the Bedtime Bank only; of these, 16 in each group completed that stage. In the second stage, participants were redistributed across six groups (ranging from 5 to 7 people each), some continuing their original treatment and some mo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01269463 · results posted 13 December 2022
According to the results reported on ClinicalTrials.gov, this trial involved 26 children in total (13 in each group), all of whom had ADHD. The trial used a design where every participant first went through an open-label phase (where everyone received the active medication, a slow-release form of methylphenidate), followed by a two-week phase where they received either the active capsule or a dummy capsule (placebo) in a random order, then swapped. This type of design, sometimes called a "crossover", meant the trial could compare how the same children responded to each treatment. The trial was...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02824627 · results posted 30 August 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02824627) enrolled 58 young people in total — 28 in the oxytocin group and 30 in the placebo group. By the end of the study, 25 and 27 participants respectively had completed it, with 3 in each group not finishing. The trial was measuring irritability and emotional reactivity in children and adolescents, using self-reported questionnaires, a clinician's rating scale, and brain imaging scans. The reported data shows the following numbers for the two main (primary) outcome measures. On the Affective Reactivity Index — a sel...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03597789 · results posted 16 August 2021
According to the results reported on ClinicalTrials.gov, this trial looked at a programme called "Helping the Non-Compliant Child Treatment." A total of 45 people started the study, though only 10 completed it — meaning 35 participants did not finish. The trial used parent-reported questionnaires to measure changes in children's difficult behaviours and in how parents manage their own emotions and respond to their children's distress. The reported data shows the following changes from the start of the study to the end. For the main outcome measures, parents' ratings of how intensely their chi...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03247556 · results posted 2 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03247556) looked at a medication called SPN-812 in children and adolescents with ADHD. A total of 296 young people took part — 97 were given a placebo (a dummy treatment with no active ingredient), 100 received a 400 mg daily dose of SPN-812, and 99 received a 600 mg daily dose. The trial ran for seven weeks and used several questionnaires to track changes in ADHD symptoms, everyday functioning, and parental stress, as rated by parents and clinicians. The reported data shows that the main thing being measured was change i...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03446885 · results posted 24 June 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03446885) involved 22 adults in total — 12 were assigned to receive Vyvanse first and 10 were assigned to receive a placebo first. This was a crossover design, meaning participants took each treatment for a period and then switched, so both groups were eventually compared on the same measures. The trial was measuring how people performed on three work-related tasks — writing a job application, completing a simulated job interview, and doing a workplace productivity exercise — as well as how inattentive or overactive they a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02287038 · results posted 3 April 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02287038) involved 44 adults in total — 23 in one group and 21 in another. It used a "crossover" design, meaning participants took atomoxetine (a medication used for ADHD) for one period and a placebo (a dummy treatment with no active ingredient) for another period, in different orders. By the end of the trial, 18 people in each group had completed the study. The trial was measuring ADHD symptom levels and quality of life, using two questionnaires filled in by participants themselves. The reported data shows the following...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01733680 · results posted 20 July 2018
According to the results reported on ClinicalTrials.gov, this trial (NCT01733680) enrolled just three participants in total — two in the amiloride group and one in the placebo group. It was investigating whether amiloride (a medication more commonly used for fluid retention) might reduce symptoms in adults with ADHD. The trial measured three things: a clinician's overall impression of change (the CGI Improvement scale), an 18-question ADHD symptom rating completed by a clinician (the AISRS), and a 75-question self-report questionnaire about everyday thinking and planning skills (the BRIEF-A)....
-
NCT01986062 · results posted 19 April 2016
According to the results reported on ClinicalTrials.gov, this trial enrolled 97 children or young people in total — 47 in one group and 50 in another. It was a crossover study, meaning everyone took both the active treatment (a medication called AR11, an amphetamine sulfate) and a placebo (a dummy treatment with no active ingredient) for one week each, in a randomised order. The trial was measuring ADHD-related behaviour and attention during structured classroom-style days, using two rating tools: the SKAMP scale (where trained observers rated behaviour and attention) and a maths task (the PER...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00610441 · results posted 29 August 2014
According to the results reported on ClinicalTrials.gov, this trial looked at an investigational medicine called MK-8777 in adults with ADHD. A total of 67 people were enrolled across four groups, and the trial used a "crossover" design — meaning participants took either MK-8777 or a dummy pill (placebo) for three weeks, had a two-week break, and then swapped to the other treatment for another three weeks. Two dosing approaches were tested: a fixed dose of 100 mg and a rising dose of 100–300 mg. The main thing being measured was change in ADHD symptom severity, using a clinician-rated checklis...
-
NCT00758160 · results posted 8 April 2014
According to the results reported on ClinicalTrials.gov, this trial enrolled 296 children and young people with ADHD (Attention Deficit Hyperactivity Disorder), all of whom received a medication called OROS methylphenidate (a slow-release form of a commonly used ADHD medicine). Of those who started, 230 completed the trial and 66 did not finish. The trial was measuring changes in ADHD-related behaviours as rated by parents using a questionnaire called the SNAP-IV — which scores things like inattentiveness, hyperactivity, and oppositional behaviour — as well as changes in parents' own psycholog...
-
NCT01060150 · results posted 31 July 2013
According to the results reported on ClinicalTrials.gov, this trial enrolled 115 young people (adolescents) diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD), all of whom received a medication called OROS Methylphenidate HCl. Of these, 113 actually received the medication and 92 completed the study, while 23 did not finish. The trial was measuring ADHD symptom severity, a clinician's overall impression of how unwell participants appeared, learning skills, and attention-related performance — all assessed using standard rating scales and tests. The reported data shows that, at the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00700427 · results posted 29 May 2013
According to the results reported on ClinicalTrials.gov, this trial involved adults with ADHD and was conducted in several stages. In the first open-label stage, 2,017 people started taking atomoxetine, and around 1,006 completed that phase. Those who responded well moved into a blinded maintenance phase (1,005 participants), and those who continued responding were then randomly assigned to either stay on atomoxetine (266 people) or switch to a placebo — a dummy tablet with no active ingredient (258 people) — without knowing which they were receiving. A final open-label extension involved 180...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00573859 · results posted 7 November 2011
According to the results reported on ClinicalTrials.gov, this trial involved 27 adult participants who had both ADHD and were smokers. The study used a crossover design, meaning the same participants took part in two phases: one where they took ADHD medication and one where they took a placebo (a dummy pill with no active ingredient). Within each phase, participants were also asked to either smoke as usual or go without smoking overnight before testing. Of the 27 who started, 15 completed both phases and 12 did not finish. The trial was measuring how ADHD medication compared to placebo in rela...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00760747 · results posted 1 September 2011
According to the results reported on ClinicalTrials.gov, this trial looked at two different ways of switching children with ADHD from one medication to another — a "slow switching" approach and a "fast switching" approach. A total of 57 children were in the slow switching group and 55 in the fast switching group at the start of the main study period. The trial measured changes in ADHD symptom scores, as well as ratings of day-to-day difficulties and overall quality of life, over a 10-week period. The reported data shows that the main outcome — a standard ADHD symptom rating scale scored from...
-
NCT00586157 · results posted 25 January 2011
According to the results reported on ClinicalTrials.gov, this trial involved 30 participants in total — 15 in each group. It was a "crossover" study, meaning each participant tried both the active treatment (called MTS, or Drug A) and a placebo (a dummy treatment with no active ingredient) at different points during the trial, so that results from the same people could be compared across both conditions. The trial was measuring changes in ADHD-related behaviours using rating scales completed by investigators and parents/guardians, where lower scores indicate less severe symptoms. The reported...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00190684 · results posted 17 January 2011
According to the results reported on ClinicalTrials.gov, this trial enrolled 1,553 people (with 1,551 receiving at least one dose of the study drug, atomoxetine, a medication used for ADHD). The trial tracked participants over up to five years, and its main focus was on monitoring physical measurements — specifically blood pressure, pulse rate, body weight, height, and temperature — to see how these changed over time. Notably, only 64 participants completed the full study period, while 1,489 did not complete it; the reasons for not completing were not detailed in the data provided here. The r...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00406354 · results posted 12 February 2010
According to the results reported on ClinicalTrials.gov, this trial enrolled 181 children across three groups: 60 received atomoxetine with a faster dose increase ("fast titration"), 61 received atomoxetine with a slower dose increase ("slow titration"), and 60 received a placebo (a dummy treatment with no active ingredient). The trial was measuring symptoms of Oppositional Defiant Disorder (ODD) — a pattern of challenging, defiant behaviour — as its main focus, and also tracked broader ADHD-related symptoms such as inattention and hyperactivity/impulsivity. By the end of the treatment period,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00501293 · results posted 15 January 2010
According to the results reported on ClinicalTrials.gov, this trial involved children and adolescents with ADHD and was made up of two back-to-back periods. In the first period (the "optimisation" phase), 110 participants had previously used a methylphenidate skin patch (a type of ADHD medication worn on the skin) and 53 had previously used a placebo (an inactive patch). Almost all participants moved into the second period (the "maintenance" phase), but by the end of that phase, roughly half in each group had not completed the study — 46 out of 109 in the patch group and 28 out of 53 in the pl...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00151996 · results posted 26 November 2009
According to the results reported on ClinicalTrials.gov, this trial enrolled 75 children in total — 42 who had previously been taking methylphenidate (a common ADHD medication) and 33 who had previously been taking amphetamine-based medication. Both groups then switched to a medication called SPD503 (also known as guanfacine extended-release). The trial ran for 6 weeks and was mainly measuring changes in ADHD symptom scores on a standardised rating scale completed by clinicians, known as the ADHD-RS-IV. By the end of the trial, 37 participants in the methylphenidate group and 26 in the ampheta...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00337285 · results posted 17 July 2009
According to the results reported on ClinicalTrials.gov, this trial involved 349 people who received Vyvanse (lisdexamfetamine) and were followed for up to one year. The trial was measuring changes in ADHD symptoms over time, using established rating scales to track things like attention and behaviour, sleep quality, and an overall clinical impression of how participants were doing. The reported data shows that, on the main measurement — a standard ADHD symptom rating scale scored from 0 (no symptoms) to 54 (most severe) — the average score across participants dropped by 24.8 points from wher...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, ADHD attracts a very large amount of public research investment from the United States government. That level of funding has remained broadly steady from one year to the next, which suggests the field is not being wound back or deprioritised. For patients, this kind of sustained, large-scale investment generally means that scientific interest in the condition remains...
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.